Remix Therapeutics is a biotechnology company focusing on modulating RNA processing through small molecule therapies to address the underlying causes of disease, according to a Jan. 5 release from the company.
Dr. Bowden previously served as the chief medical officer and a strategy adviser for Agios from 2014 to 2022. He also spent eight years at Genentech, where he was the vice president of product development oncology.
Dr. Bowden also has experience as the executive director of the Europe, Middle East and Africa regions for New York-based pharmaceutical company Bristol-Myers Squibb.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
